{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:20:11Z","timestamp":1793892011965,"version":"4.8.0"},"reference-count":30,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T00:00:00Z","timestamp":1583884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010609","name":"Gda\u0144ski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["01-0322\/08\/402"],"award-info":[{"award-number":["01-0322\/08\/402"]}],"id":[{"id":"10.13039\/501100010609","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Animals"],"abstract":"<jats:p>The emergence of staphylococcal canine pathogens resistant to multiple antimicrobial agents is a growing and urgent problem in veterinary practice. Antimicrobial peptides (AMPs) seem to be a promising alternative to conventional antibiotics. The aim of this in vitro study was to evaluate the antimicrobial activity of selected AMPs against pathogenic staphylococcal strains, including multidrug- and methicillin-resistant strains isolated from canine pyoderma cases. Seven antimicrobial peptides (aurein 1.2, CAMEL, citropin 1.1, protegrin-1, pexiganan, temporin A and uperin 3.6) synthesized by the 9-fluorenylmethoxycarbonyl (Fmoc) solid-phase method were tested. The minimal inhibitory and minimal bactericidal concentrations (MIC and MBC) were determined by the broth microdilution method. The study showed that analyzed AMPs exerted an extensive effect against canine pathogens, with the most active peptide being uperin 3.6. The tested AMPs were equally efficient against both resistant- and susceptible staphylococcal strains and were more efficient against Staphylococcus pseudintermedius than against Staphylococcus aureus strains. Our findings are particularly interesting from a clinical perspective, as they point to AMPs as potential therapeutic topical agents in canine pyoderma cases associated with antimicrobial resistance of staphylococci.<\/jats:p>","DOI":"10.3390\/ani10030470","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T04:13:57Z","timestamp":1583986437000},"page":"470","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["In Vitro Efficiency of Antimicrobial Peptides against Staphylococcal Pathogens Associated with Canine Pyoderma"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6468-7233","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Jarosiewicz","sequence":"first","affiliation":[{"name":"Department of Oral Microbiology, Faculty of Medicine, Medical University of Gdansk, Gdansk, 25 D\u0119bowa Str., 80-204 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9359-7966","authenticated-orcid":false,"given":"Katarzyna","family":"Garbacz","sequence":"additional","affiliation":[{"name":"Department of Oral Microbiology, Faculty of Medicine, Medical University of Gdansk, Gdansk, 25 D\u0119bowa Str., 80-204 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3230-6878","authenticated-orcid":false,"given":"Damian","family":"Neubauer","sequence":"additional","affiliation":[{"name":"Department of Inorganic Chemistry, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, 107 Gen. J. Hallera Str., 80-416 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Kamysz","sequence":"additional","affiliation":[{"name":"Department of Inorganic Chemistry, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, 107 Gen. J. Hallera Str., 80-416 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/vr.158.16.533","article-title":"Survey of the prevalence, diagnosis and treatment of dermatological conditions in small animals in general practice","volume":"158","author":"Hill","year":"2006","journal-title":"Vet. Rec."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.vetmic.2011.02.002","article-title":"Risk factors associated with the antimicrobial resistance of staphylococci in canine pyoderma","volume":"150","author":"Huerta","year":"2011","journal-title":"Vet. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.tvjl.2018.04.002","article-title":"What has changed in canine pyoderma? A narrative review","volume":"235","author":"Loeffler","year":"2018","journal-title":"Vet. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00284-012-0254-9","article-title":"Staphylococci isolated from carriage sites and infected sites of dogs as a reservoir of multidrug resistance and methicillin resistance","volume":"66","author":"Garbacz","year":"2013","journal-title":"Curr. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.tvjl.2013.11.014","article-title":"Canine superficial bacterial folliculitis: Current understanding of its etiology, diagnosis and treatment","volume":"199","author":"Bloom","year":"2014","journal-title":"Vet. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-biochem-060614-034516","article-title":"Mechanisms of methicillin resistance in Staphylococcus aureus","volume":"84","author":"Peacock","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1099\/jmm.0.000585","article-title":"Borderline oxacillin-resistant Staphylococcus aureus (BORSA)\u2013a more common problem than expected?","volume":"66","author":"Hryniewicz","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: Current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Molchanova, N., Hansen, P.R., and Franzyk, H. (2017). Advances in development of antimicrobial peptidomimetics as potential drugs. Molecules, 22.","DOI":"10.3390\/molecules22091430"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Greco, I., Hummel, B.D., Vasir, J., Watts, J.L., Koch, J., Johannes, E., Hansen, J.E., Nielsen, H.M., Damborg, P., and Hansen, P.R. (2018). In vitro adme properties of two novel antimicrobial peptoid-based compounds as potential agents against canine pyoderma. Molecules, 23.","DOI":"10.3390\/molecules23030630"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/psc.704","article-title":"Function and therapeutic potential of host defence peptides","volume":"11","author":"McPhee","year":"2005","journal-title":"J. Pept. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/jac\/dkn074","article-title":"Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections","volume":"61","author":"Fritsche","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"70033","DOI":"10.1016\/S0151-9638(10)70054-5","article-title":"What\u2019s new in acne? New therapeutic approaches","volume":"137","author":"Bettoli","year":"2010","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0714.2011.01094.x","article-title":"The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: Analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial","volume":"41","author":"Elad","year":"2012","journal-title":"J. Oral Pathol. Med."},{"key":"ref_15","first-page":"6","article-title":"Topical antimicrobial agents for treating foot ulcers in people with diabetes","volume":"14","author":"Dumville","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.rvsc.2017.05.021","article-title":"Evaluation of the in vitro effect of Boldo and Meadowsweet plant extracts on the expression of antimicrobial peptides and inflammatory markers in canine keratinocytes","volume":"115","author":"Santoro","year":"2017","journal-title":"Res. Vet. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.tvjl.2013.08.020","article-title":"Broad-spectrum activity of a novel antibiotic peptide against multidrug-resistant veterinary isolates","volume":"198","author":"Cabassi","year":"2013","journal-title":"Vet. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12941-017-0193-1","article-title":"Activity of AMP2041 against human and animal multidrug resistant Pseudomonas aeruginosa clinical isolates","volume":"16","author":"Cabassi","year":"2017","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00430-019-00624-7","article-title":"In vitro activity of Protegrin-1, alone and in combination with clinically useful antibiotics, against Acinetobacter baumannii strains isolated from surgical wounds","volume":"208","author":"Morroni","year":"2019","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4161\/viru.23526","article-title":"Pathogenicity potential of Staphylococcus pseudintermedius strains isolated from canine carriers and from dogs with infection signs","volume":"4","author":"Garbacz","year":"2013","journal-title":"Virulence"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1128\/JCM.01915-08","article-title":"Molecular diagnostic identification of Staphylococcus pseudintermedius","volume":"47","author":"Bannoehr","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/jcm.30.7.1654-1660.1992","article-title":"Detection of Staphylococcus aureus by polymerase chain reaction amplification of the nuc gene","volume":"30","author":"Brakstad","year":"1992","journal-title":"J. Clin. Microbiol."},{"key":"ref_23","unstructured":"Clinical and Laboratory Standards Institute (2013). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement, Clinical and Laboratory Standards Institute. Document VET01-A."},{"key":"ref_24","unstructured":"Clinical and Laboratory Standards Institute (2015). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement, Clinical and Laboratory Standards Institute. Document M100-S25."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1128\/AAC.00275-07","article-title":"Update to the multiplex PCR strategy for assignment of mec element types in Staphylococcus aureus","volume":"51","author":"Milheirico","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/21505594.2016.1213475","article-title":"Activity of antimicrobial peptides, alone or combined with conventional antibiotics, against Staphylococcus aureus isolated from the airways of cystic fibrosis patients","volume":"8","author":"Garbacz","year":"2017","journal-title":"Virulence"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"163-e43","DOI":"10.1111\/vde.12118","article-title":"Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases)","volume":"25","author":"Hillier","year":"2014","journal-title":"Vet. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1034\/j.1399-3011.1999.00095.x","article-title":"The solution structure of uperin 3.6, an antibiotic peptide from the granular dorsal glands of the Australian toadlet, Uperoleia mjobergii","volume":"54","author":"Chia","year":"1999","journal-title":"J. Pept. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1128\/AAC.49.9.3933-3936.2005","article-title":"In vitro activity and killing effect of uperin 3.6 against gram-positive cocci isolated from immunocompromised patients","volume":"49","author":"Giacometti","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","first-page":"270932","article-title":"Activity of antimicrobial peptides and conventional antibiotics against superantigen positive Staphylococcus aureus isolated from the patients with neoplastic and inflammatory erythrodermia. Chemother","volume":"2011","author":"Cirioni","year":"2011","journal-title":"Res. Pract."}],"container-title":["Animals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2615\/10\/3\/470\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:06:10Z","timestamp":1760173570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2615\/10\/3\/470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,11]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["ani10030470"],"URL":"https:\/\/doi.org\/10.3390\/ani10030470","relation":{},"ISSN":["2076-2615"],"issn-type":[{"value":"2076-2615","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,11]]}}}